Price controls sap resources and ingenuity from America’s pharmaceutical sector — and deprive American patients of the next generation of life-saving medicines.
President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 weight-loss drugs dispensed through Medicare and Medicaid. Both firms have also agreed to sell the drugs at lower prices on Trump’s yet-to-be-developed online marketplace for prescription drugs, TrumpRx.
Lilly and Novo join Pfizer and AstraZeneca in striking agreements with the administration to lower the prices of at least some of their drugs. The president has framed these deals as vindications of his “Most Favored Nation” executive order, which envisions requiring drug companies to offer Americans the best price they offer residents of other developed nations.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
The real story behind Trump’s GLP-1 price cut: Markets still rule
Sally C. Pipes
Price controls sap resources and ingenuity from America’s pharmaceutical sector — and deprive American patients of the next generation of life-saving medicines.
President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 weight-loss drugs dispensed through Medicare and Medicaid. Both firms have also agreed to sell the drugs at lower prices on Trump’s yet-to-be-developed online marketplace for prescription drugs, TrumpRx.
Lilly and Novo join Pfizer and AstraZeneca in striking agreements with the administration to lower the prices of at least some of their drugs. The president has framed these deals as vindications of his “Most Favored Nation” executive order, which envisions requiring drug companies to offer Americans the best price they offer residents of other developed nations.
Read the entire op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.